Moreover, the expression of CD163 in primary tumor tissue was significantly higher than that in adjacent normal tissue at both the mRNA and protein levels in RCC patients based on the TCGA and Clinical Proteomic Tumor Analysis Consortium (CPTAC) databases (Fig. 1F). Here, CD163 is linked to renal cell carcinoma.